Q4 2025 Harmony Biosciences Holdings Inc Earnings Call Transcript
Key Points
- Harmony Biosciences Holdings Inc (HRMY) reported strong financial performance with a 21% increase in net revenues for Q4 2025, reaching $243.8 million.
- The company achieved record-setting performance for WAKIX, with three consecutive quarters of over 400 average patient adds.
- Harmony Biosciences Holdings Inc (HRMY) is on track to achieve blockbuster status for WAKIX in 2026, with projected net revenue between $1 billion and $1.04 billion.
- The company has made significant progress in securing intellectual property for WAKIX, settling with 6 of 7 generic filers, potentially delaying generic entry until March 2030.
- Harmony Biosciences Holdings Inc (HRMY) has a robust late-stage pipeline with five ongoing Phase 3 registrational trials for distinct CNS indications, positioning it for long-term growth.
- Operating expenses increased significantly in Q4 2025, reaching $136.7 million, driven by R&D investments and litigation expenses.
- Non-GAAP adjusted net income for Q4 2025 decreased to $33.4 million from $64.2 million in the prior quarter.
- The company faces competition in patient enrollment for its Phase 3 narcolepsy and idiopathic hypersomnia studies.
- There is ongoing litigation regarding WAKIX's intellectual property, with potential implications for market exclusivity.
- The company anticipates typical seasonal dynamics in Q1 2026, including higher gross-to-net deductions and potential inventory drawdowns.
Thank you for your continued patience. Your meeting will begin shortly. (Operator Instructions)
Good morning. My name is Angela and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences' fourth quarter and full year 2025 financial results conference call.
All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. (Operator Instructions) Please be advised that today's conference may be recorded.
I will now turn the call over to Matthew Beck from Astr Partners. Please go ahead.
Thank you operator. Good morning everyone and thank you for joining us today as we review Harmony Biosciences' fourth quarter 2025 financial results and provide a business update. Before we start, I encourage everyone to go to the investor section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
